AbbVie acquires Celsius Therapeutics, Inc.

AbbVie acquired Celsius Therapeutics, Inc. for $250 million upfront, a transaction announced in June 2024, structured as cash upfront (asset acquisition).

Celsius Therapeutics, Inc. operates in Immunology (IBD), is based in Cambridge, Massachusetts. Celsius is a privately held biotech pioneering therapies for inflammatory disease. Its lead investigational asset, CEL383, is a potential first-in-class anti-TREM1 antibody for inflammatory bowel disease that had completed a Phase 1 study. The FY2024 10-K records a $250 million upfront charge related to the acquisition.

Adds a first-in-class anti-TREM1 IBD antibody to AbbVie's immunology pipeline.

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.